Yuko Murakami

Summary

Affiliation: National Institute of Infectious Diseases
Country: Japan

Publications

  1. ncbi Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle
    Yuko Murakami
    Department of Bioactive Molecules, National Institute of Infectious Diseases, Toyama 1 23 1, Shinjuku ku, Tokyo 162 8640, Japan
    Microbes Infect 15:45-55. 2013
  2. ncbi Identification of bisindolylmaleimides and indolocarbazoles as inhibitors of HCV replication by tube-capture-RT-PCR
    Yuko Murakami
    Department of Bioactive Molecules, National Institute of Infectious Diseases, Shinjuku ku, Tokyo, Japan
    Antiviral Res 83:112-7. 2009
  3. ncbi Nucleolar Nek11 is a novel target of Nek2A in G1/S-arrested cells
    Kohji Noguchi
    Department of Bioactive Molecules, National Institute of Infectious Diseases, 1 23 1 Toyama, Shinjuku ku, Tokyo 162 8640, Japan
    J Biol Chem 279:32716-27. 2004
  4. ncbi BimEL is an important determinant for induction of anoikis sensitivity by mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitors
    Hidesuke Fukazawa
    Department of Bioactive Molecules, National Institute of Infectious Diseases, 1 23 1 Toyama, Shinjuku ku, Tokyo 162 8640, Japan
    Mol Cancer Ther 3:1281-8. 2004
  5. ncbi Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus through interaction with Daxx
    Yuko Murakami
    Department of Bioactive Molecules, National Institute of Infectious Diseases, Tokyo 162, Japan
    J Biol Chem 281:28113-21. 2006
  6. ncbi Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway
    Hidesuke Fukazawa
    Department of Bioactive Molecules, National Institute of Infectious Diseases, Tokyo 162 8640, Japan
    Mol Cancer Ther 1:303-9. 2002
  7. ncbi A cell-based, microplate colorimetric screen identifies 7,8-benzoflavone and green tea gallate catechins as inhibitors of the hepatitis C virus
    Hidesuke Fukazawa
    Department of Bioactive Molecules, National Institute of Infectious Diseases, Tokyo, Japan
    Biol Pharm Bull 35:1320-7. 2012
  8. ncbi Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies
    Kohji Noguchi
    Department of Bioactive Molecules, National Institute of Infectious Diseases, 1 23 1 Toyama, Shinjuku ku, Tokyo 162 8640, Japan
    Cancer Sci 98:1288-96. 2007
  9. ncbi [Screening of protein kinase inhibitors]
    Yoshimasa Uehara
    National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan
    Gan To Kagaku Ryoho 31:491-4. 2004
  10. ncbi Nek11, a new member of the NIMA family of kinases, involved in DNA replication and genotoxic stress responses
    Kohji Noguchi
    Department of Bioactive Molecules, National Institute of Infectious Diseases, 1 23 1 Toyama, Shinjuku ku, Tokyo 162 8640, Japan
    J Biol Chem 277:39655-65. 2002

Detail Information

Publications13

  1. ncbi Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle
    Yuko Murakami
    Department of Bioactive Molecules, National Institute of Infectious Diseases, Toyama 1 23 1, Shinjuku ku, Tokyo 162 8640, Japan
    Microbes Infect 15:45-55. 2013
    ..Taken together, SERMs seemed to target multiple steps of HCV viral life cycle: attachment, entry, replication, and post replication events. SERMs may be potential candidates for the treatment of HCV infection...
  2. ncbi Identification of bisindolylmaleimides and indolocarbazoles as inhibitors of HCV replication by tube-capture-RT-PCR
    Yuko Murakami
    Department of Bioactive Molecules, National Institute of Infectious Diseases, Shinjuku ku, Tokyo, Japan
    Antiviral Res 83:112-7. 2009
    ..These series of compounds represent new classes of inhibitors that may warrant further development...
  3. ncbi Nucleolar Nek11 is a novel target of Nek2A in G1/S-arrested cells
    Kohji Noguchi
    Department of Bioactive Molecules, National Institute of Infectious Diseases, 1 23 1 Toyama, Shinjuku ku, Tokyo 162 8640, Japan
    J Biol Chem 279:32716-27. 2004
    ..Nek2 dissociated this autoinhibitory interaction. Altogether, our studies demonstrate a unique mechanism of Nek11 activation by Nek2A in G(1)/S-arrested cells and suggest a novel possibility for nucleolar function of the NIMA family...
  4. ncbi BimEL is an important determinant for induction of anoikis sensitivity by mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitors
    Hidesuke Fukazawa
    Department of Bioactive Molecules, National Institute of Infectious Diseases, 1 23 1 Toyama, Shinjuku ku, Tokyo 162 8640, Japan
    Mol Cancer Ther 3:1281-8. 2004
    ..We conclude that MEK inhibitors sensitize MDA-MB231 and HBC4 cells to anoikis by blocking phosphorylation and hence degradation of BimEL, a mechanism that these cells depend on to escape anoikis...
  5. ncbi Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus through interaction with Daxx
    Yuko Murakami
    Department of Bioactive Molecules, National Institute of Infectious Diseases, Tokyo 162, Japan
    J Biol Chem 281:28113-21. 2006
    ..These results suggested that LANA contributes to a high expression of VEGF receptors in KS lesion by interfering with the interaction between Daxx and Ets-1...
  6. ncbi Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway
    Hidesuke Fukazawa
    Department of Bioactive Molecules, National Institute of Infectious Diseases, Tokyo 162 8640, Japan
    Mol Cancer Ther 1:303-9. 2002
    ..Inhibitors of MEK-ERK and mTOR-p70(S6K) pathways may provide a therapeutic strategy to selectively target neoplasms proliferating at ectopic locations, with acceptable effects on normal cells in their proper tissue context...
  7. ncbi A cell-based, microplate colorimetric screen identifies 7,8-benzoflavone and green tea gallate catechins as inhibitors of the hepatitis C virus
    Hidesuke Fukazawa
    Department of Bioactive Molecules, National Institute of Infectious Diseases, Tokyo, Japan
    Biol Pharm Bull 35:1320-7. 2012
    ..This assay is simple, reliable and cost-effective; does not require any specially engineered cell lines or viruses; and should be useful in the identification of compounds with anti-HCV activity...
  8. ncbi Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies
    Kohji Noguchi
    Department of Bioactive Molecules, National Institute of Infectious Diseases, 1 23 1 Toyama, Shinjuku ku, Tokyo 162 8640, Japan
    Cancer Sci 98:1288-96. 2007
    ..The present review gives a simple outline of the functional interactions between KSHV- and EBV-viral gene products and host cell deregulated signaling pathways as possible targets of chemotherapy against AIDS-related malignancies...
  9. ncbi [Screening of protein kinase inhibitors]
    Yoshimasa Uehara
    National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan
    Gan To Kagaku Ryoho 31:491-4. 2004
    ..Here, we briefly described some of the protein kinase inhibitors that have been approved or are under clinical development, and present some novel inhibitors that were found in our screening system...
  10. ncbi Nek11, a new member of the NIMA family of kinases, involved in DNA replication and genotoxic stress responses
    Kohji Noguchi
    Department of Bioactive Molecules, National Institute of Infectious Diseases, 1 23 1 Toyama, Shinjuku ku, Tokyo 162 8640, Japan
    J Biol Chem 277:39655-65. 2002
    ..Collectively, these results suggest that Nek11 has a role in the S-phase checkpoint downstream of the caffeine-sensitive pathway...
  11. ncbi Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses
    Yukihiro Kaneko
    Department of Chemotherapy and Mycosis, National Institute of Infectious Diseases, Tokyo, Japan
    Med Mycol 48:606-12. 2010
    ..Our results may provide clues as to the mechanism of increased drug resistance in Candida biofilms and raises concerns about the use of the voriconazole-micafungin combination in clinical settings...
  12. ncbi Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia
    Izumi Fukuda
    Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University, Tokyo, Japan
    Growth Horm IGF Res 16:211-6. 2006
    ..The BMI (21.4+/-0.6 kg/m2) and serum total protein levels (6.6+/-0.1g/dl) were preserved at the occurrence of first hypoglycemic attack suggesting that malnutrition might not be the main cause of hypoglycemia in most patients...
  13. ncbi A mammalian two-hybrid screening system for inhibitors of interaction between HIV Nef and the cellular tyrosine kinase Hck
    Yuko Murakami
    Department of Bioactive Molecules, National Institute of Infectious Diseases, 1 23 1, Toyama, Shinjuku ku, 162 8640, Tokyo, Japan
    Antiviral Res 55:161-8. 2002
    ..Using the second system, we found that adriamycin interfered with the Nef-Hck interaction by reducing the amount of the Hck protein. The mammalian two-hybrid system may show utility in screening inhibitors of Nef-Hck interaction...